Transparency

Transparency of the transfers of value between the pharmaceutical industries, healtcare professionals and healtcare organisations

Publication of the data concerning relationships between companies and medical practitioners: Responsible Transparency

The data relating to the collaboration relationships between Alfasigma S.p.A. and Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and Research and Development (R&D) referring to the period 2015-2016 are available on our website.

Absolute transparency through the publication of this data was the choice made by pharmaceutical companies with complete conviction, adopting Farmindustria's Code on Disclosure in implementation of the EFPIA (European Federation of Pharmaceutical Industries and Associations) Code.

The collaboration between the pharmaceutical companies and medical practitioners, which has been extremely well-regulated for some time, can be broken down into various spheres of activity:

  1. research and development of new medicines through clinical trials conducted in hospitals, universities and public and private health facilities;
  2. scientific consultancy;
  3. seminars and scientific conventions that provide information and updates;
  4. support for CME (Continuing Medical Education) conferences and courses organised by public institutions, universities, scientific societies and accredited CME providers.

It is the exchange of knowledge between companies and medical practitioners, with their wealth of know-how and experience in the field, that allows information to be collected that is useful in research and development, and thereby make available increasingly efficacious medicines to meet the health needs of patients.

These relationships, in addition to being governed by national and international regulations, are based on reciprocal respect for the roles within a transparent framework of the ethical standards of Farmindustria, which lay down strict controls performed in accordance with the precise procedures dictated by third-party bodies, presided over by judges appointed by the President of the Court of Cassation.

You can access the data - published in complete accordance with the Italian regulations on privacy - concerning individual professionals who have signed the agreement and, in aggregate form, all the others.


Note on accounting aspects

Alfa Wasserman's published figures are recorded in compliance with VAT regulations in force. They are presented without VAT and according to the principle of cash. Figures in foreign currencies are converted into Euros at the exchange rate current as of the date of recording.

Sigma-Tau's, Biofutura's and Avangarde's published figures are recorded in compliance with VAT regulations in force. They are presented without VAT and according to the principle of competence. Figures in foreign currencies are converted into Euros at the exchange rate current as of the date of recording.

Further information on the new regulatory provisions introduced with the "Code on Disclosure of Transfers of Value From Pharmaceutical Companies to Healthcare Professionals and Healthcare Organizations" are available from the www.farmindustria.it website (Home/Code of Ethics page).


Alfa Wassermann 2015 List

Alfa Wassermann 2016 List

Avantgarde 2015 List

Avantgarde 2016 List

Biofutura 2015 List

Biofutura 2016 List

Sigma-Tau 2015 List

Sigma-Tau 2016 List

For many years, Alfasigma has supported Patients' Associations, in accordance with those values and principles that lead to a better, healthier life.

Alfasigma collaborates with many patients’ associations in order to support their programs and activities. This support takes many forms, including donations and sponsorship, with the aim of encouraging efforts to improve the health of the community and work for a healthier world. Collaborating with these associations allows Alfasigma to better understand the needs of the patients that use its medicines. At the same time, it allows us to help these organizations in the dissemination of scientific information in order to meet the requirements of those in need in the best possible way.

Alfasigma is committed to the principle of transparency, that is, the disclosure of activities that reflect the company’s engagement in initiatives in the public interest.


2010 - 30,000 Euro to the Associazione Italiana Pazienti Anticoagulanti (A.I.P.A.), (Italian Association for Anticoagulant Patients) Milan Section – San Raffaele Onlus, to support scientific research in the area of concern to patients undergoing anticoagulant therapy.

2012 - 5,000 Euro to the Associazione Malati Reumatici Emilia Romagna (AMRER) (Emilia Romagna Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2012 - 2,000 Euro to the Associazione Sarda Malati Reumatici (ASMAR) (Sardinian Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2013 - 5,000 Euro to the Associazione Malati Reumatici Emilia Romagna (APMAR) (Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2013 - 2,000 Euro to the Associazione Malati Reumatici Emilia Romagna (AMRER) (Emilia Romagna Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2014 - 5.000 Euro to the Associazione Malati Reumatici Emilia Romagna (APMAR) (Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2015 - 5,000 Euro to the Associazione Malati Reumatici Emilia Romagna (AMRER) (Emilia Romagna Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2015 - 4.400 Euro to the Associazione Lombarda Malati Reumatici (ALOMAR) – Onlus, in order to support the association’s dissemination activities.

2015 - 5.000 Euro to the Associazione Malati Reumatici Emilia Romagna (APMAR) (Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2015 - 4.000 Euro to the Associazione Laziale Malati Reumatici (ALMAR) (Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2016 - 8,000 Euro to the Associazione Malati Reumatici Emilia Romagna (AMRER) (Emilia Romagna Association for Rheumatic Diseases) – Onlus, in order to support the association’s dissemination activities.

2016 - 10,000 Euro to the Associazione EPAC – Onlus, in order to support the association’s dissemination activities.


Alfasigma born as pharmaceutical industry August 1, 2017. The partnerships 2010-2016 are intended to Alfa Wassermann competence.